New Data Show Oral Semaglutide Significantly Reduced A1C in Adults with Type 2 Diabetes
Newly published findings from the PIONEER 1 phase 3a trial show that once-daily once-daily oral semaglutide was associated with significant reductions in blood sugar in adults with type 2 diabetes.
Newly published findings from the PIONEER 1 phase 3a trial show that once-daily once-daily oral semaglutide was associated with significant reductions in blood sugar in adults with type 2 diabetes.
The PIONEER 1 trial implemented 2 approaches to the evaluation—an intention-to-treat principle to explore the treatment effect (including that of rescue medications), and an on-treatment principle to observe the effect while on the trial product and without the use of rescue medications.
Announced at the American Diabetes Association’s 78th Annual Scientific Sessions in Orlando, Florida, the data was gathered in an evaluation of the Novo Nordisk glucagon-like peptide-1 (GLP-1) analogue’s safety and efficacy in doses of 3 mg, 7 mg, and 14 mg as monotherapy over the course of 26 weeks. The trial randomized 703 patients 1:1:1:1 to the 1 of the 3 doses of semaglutide or placebo.
Click to continue reading on MD Magazine.
